43 related articles for article (PubMed ID: 8587696)
1. Bosentan attenuates sickle cell disease erythrocyte HbS polymerization and impaired deformability induced by endothelin-1.
Rosa Teixeira-Alves L; Guimarães-Nobre CC; Mendonça-Reis E; Miranda-Alves L; Berto-Junior C
Can J Physiol Pharmacol; 2023 Dec; 101(12):642-651. PubMed ID: 36821840
[TBL] [Abstract][Full Text] [Related]
2. The effects of endothelin receptor blockade by bosentan on the healing of a bowel anastomosis in an experimental Crohn's disease model.
Kirkil C; Cetinkaya Z; Ustundag B; Akpolat N; Ayten R; Bulbuller N
J Gastrointest Surg; 2008 Aug; 12(8):1429-35. PubMed ID: 18484142
[TBL] [Abstract][Full Text] [Related]
3. Effect of endothelin receptor antagonists on clinically relevant outcomes after experimental subarachnoid hemorrhage: a systematic review and meta-analysis.
Laban KG; Vergouwen MD; Dijkhuizen RM; Sena ES; Macleod MR; Rinkel GJ; van der Worp HB
J Cereb Blood Flow Metab; 2015 Jul; 35(7):1085-9. PubMed ID: 25944590
[TBL] [Abstract][Full Text] [Related]
4. The primary vascular dysregulation syndrome: implications for eye diseases.
Flammer J; Konieczka K; Flammer AJ
EPMA J; 2013 Jun; 4(1):14. PubMed ID: 23742177
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic reduction of angiographic vasospasm in experimental subarachnoid hemorrhage: systematic review and meta-analysis.
Zoerle T; Ilodigwe DC; Wan H; Lakovic K; Sabri M; Ai J; Macdonald RL
J Cereb Blood Flow Metab; 2012 Sep; 32(9):1645-58. PubMed ID: 22534672
[TBL] [Abstract][Full Text] [Related]
6. Role of endothelin-1 in human aneurysmal subarachnoid hemorrhage: associations with vasospasm and delayed cerebral ischemia.
Thampatty BP; Sherwood PR; Gallek MJ; Crago EA; Ren D; Hricik AJ; Kuo CW; Klamerus MM; Alexander SA; Bender CM; Hoffman LA; Horowitz MB; Kassam AB; Poloyac SM
Neurocrit Care; 2011 Aug; 15(1):19-27. PubMed ID: 21286855
[TBL] [Abstract][Full Text] [Related]
7. High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label feasibility study.
Nogueira RG; Bodock MJ; Koroshetz WJ; Topcuoglu MA; Carter BS; Ogilvy CS; Pryor JC; Buonanno FS
Neurocrit Care; 2007; 7(3):194-202. PubMed ID: 17901934
[TBL] [Abstract][Full Text] [Related]
8. [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.
Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
Neurosurg Rev; 2003 May; 26(2):125-32. PubMed ID: 12962299
[TBL] [Abstract][Full Text] [Related]
9. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA
Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855
[TBL] [Abstract][Full Text] [Related]
11. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm.
Shigeno T; Clozel M; Sakai S; Saito A; Goto K
Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696
[TBL] [Abstract][Full Text] [Related]
12. The role of endothelin in experimental cerebral vasospasm.
Roux S; Löffler BM; Gray GA; Sprecher U; Clozel M; Clozel JP
Neurosurgery; 1995 Jul; 37(1):78-85; discussion 85-6. PubMed ID: 8587695
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist.
Zimmermann M; Seifert V; Löffler BM; Stolke D; Stenzel W
Neurosurgery; 1996 Jan; 38(1):115-20. PubMed ID: 8747959
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of cerebral vasospasms after experimental subarachnoid hemorrhage by the endothelin receptor antagonist RO 47-0203].
Zimmermann M; Seifert V
Zentralbl Neurochir; 1996; 57(3):143-9. PubMed ID: 8967274
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
